Product Description
Oxaloacetate CFS™ – Clinically Proven MEDICAL FOOD for Chronic Fatigue Syndrome
Clinically Proven to Significantly Reduce Fatigue in ME/CFS Patients (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome)
Cellular Health Support
Studied in Peer-Reviewed Clinical Trials
Used by ME/CFS patients in 30 countries worldwide
Oxaloacetate is a natural human energy metabolic compound present in nearly every cell of the human body.
Oxaloacetate is needed by nearly every human cell to produce energy in the mitochondria via Krebs Cycle/Energy Cycle.
Proper levels of oxaloacetate are crucial for healthy metabolism, glucose system support, and overall cellular function.
What can Oxaloacetate CFS do for my energy levels?
Mitochondria are the engines of your cells and use a process called the Krebs Cycle to turn food and oxygen into the energy we need to live.
Oxaloacetate is a crucial metabolic compound essential to the Krebs cycle and energy production.
Using Oxaloacetate CFS to fuel your cells with ample oxaloacetate helps them create more energy, supporting your brain and body.
Clinical Research on Oxaloacetate CFS
Metabolomic studies in ME/CFS patients vs. normal controls indicate that oxaloacetate levels are significantly reduced in the plasma of ME/CFS patients:
Springer Nature’s Journal of Translational Medicine:
ME/CFS patients were given oxaloacetate dose of either 500 mg twice per day, 1000 mg twice per day or 1000 mg three times per day.
Reduction in fatigue was dose dependent with the smallest dose yielding 21.7% reduction in fatigue and the largest yielding 33.3% reduction in six weeks.
Long COVID patients were given either 500 milligrams twice per day or 1000 milligrams of oxaloacetate twice per day, with fatigue reduced by up to 46.8% in six weeks.
In summary, with taking oxaloacetate for 6 weeks:
ME/CFS patients had up to 33% reduction in fatigue
Long COVID patients had up to 47% reduction in fatigue (for those that met ME/CFS criteria)
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Frontiers In Neurology:
For those taking oxaloacetate, there was a significant reduction of fatigue by an average of 25 to 35%
40.5% of the oxaloacetate group were classified as “enhanced responders,” with an average fatigue reduction of 63%
Improvements were found in both mental and physical fatigue
2025 International ME/CFS Conference– Oxaloacetate CFS Data Presented
CFS Patients Have Low Oxaloacetate Levels
The Journal of Molecular Biosystems (2017) clinical trial showed a statistically significant shortage of oxaloacetate in ME/CFS patients compared to a normal control group.
Oxaloacetate levels are significantly reduced in the plasma of ME/CFS patients.
FDA Allows Oxaloacetate for CFS Structure/Function Claim for ME/CFS (July 2025)
Based on the results of peer-reviewed clinical trials, doctor and patient reports and the existing body of research investigating Oxaloacetate, the U.S. Food and Drug Administration has allowed the following structure/function claim for Oxaloacetate CFS:
“Oxaloacetate may help alleviate the physical and mental fatigue associated with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).”
Patented Biotechnology, Manufactured in the United States. From Terra Biological
